The most common cause of secondary parkinsonism, its clinical features that overlap deceptively with idiopathic Parkinson's disease, and the management approach when the causative agent cannot be immediately withdrawn.
Drug-induced parkinsonism (DIP) is the second most common cause of parkinsonism after idiopathic Parkinson's disease, accounting for approximately 20% of all parkinsonism cases in some series. Its clinical presentation is frequently indistinguishable from idiopathic PD on clinical examination, making the medication history the single most important diagnostic tool. The distinction matters profoundly: treating DIP with dopaminergic agents is ineffective and risks worsening the underlying psychiatric or gastrointestinal condition for which the causative drug was prescribed.
Drug-induced parkinsonism results from pharmacological blockade or depletion of dopamine at nigrostriatal synapses. The causative agents fall into several categories. Dopamine receptor antagonists are the most common cause: antipsychotics (both first-generation and second-generation agents) and the antiemetics metoclopramide and prochlorperazine. Calcium channel blockers with dopamine receptor blocking activity, particularly cinnarizine and flunarizine (not available in the United States but widely used internationally), account for a significant proportion of DIP in countries where they are prescribed. Reserpine and tetrabenazine deplete presynaptic dopamine stores and cause DIP by a different mechanism. Valproic acid causes a parkinsonian syndrome at therapeutic doses through a mechanism that may involve mitochondrial dysfunction in dopaminergic neurons.1
The clinical features of DIP overlap extensively with idiopathic PD. Both conditions present with bradykinesia, rigidity, and postural instability. Several features favor DIP over idiopathic PD: bilateral and symmetric onset (idiopathic PD is almost always asymmetric at presentation), absence of rest tremor or presence of an action tremor (idiopathic PD tremor is predominantly rest tremor), rapid onset of symptoms correlated with drug initiation or dose escalation, and resolution or improvement after drug withdrawal. However, none of these features is diagnostic, and the temporal relationship to drug exposure is the most reliable clue. Dopamine transporter (DAT) imaging with SPECT (DaTscan) can be a useful discriminator: DIP produces a normal DAT scan because the nigrostriatal pathway is structurally intact, while idiopathic PD shows reduced DAT binding reflecting actual dopaminergic neuronal loss.12
Management of DIP begins with identification and discontinuation of the causative agent whenever clinically feasible. Parkinsonism typically improves over weeks to months following drug withdrawal, though recovery can be incomplete, particularly in older patients, suggesting that drug exposure may unmask subclinical idiopathic PD in susceptible individuals. When the causative drug cannot be withdrawn because of the underlying condition it treats, substitution with a less dopamine-blocking agent should be considered: in antipsychotic-induced DIP, switching to quetiapine or clozapine (which carry minimal D2 blockade at clinical doses for psychiatric indications) may allow partial motor recovery. If anticholinergic therapy is considered for symptom management while the causative drug is still needed, trihexyphenidyl or benztropine can provide modest benefit, but cognitive effects in older patients limit utility. Levodopa is generally not helpful in DIP because the dopamine receptor is blocked and exogenous dopamine cannot act effectively at the target.1
Dopamine receptor antagonists: antipsychotics (all first-generation; risperidone, olanzapine among second-generation); metoclopramide; prochlorperazine. Dopamine depletors: reserpine; tetrabenazine; deutetrabenazine. Calcium channel blockers with D2 activity: cinnarizine; flunarizine (not US). Other: valproic acid; lithium (rare). DaTscan is normal in DIP — reduced only in idiopathic PD with true neuronal loss.
How age-related pharmacokinetic and pharmacodynamic changes, frailty, and multi-morbidity modify every prescribing decision in the elderly patient with PD.
The majority of patients with Parkinson's disease are over 65 years of age at diagnosis, and many live into their eighth and ninth decades with the disease. Age-related changes in renal clearance, hepatic metabolism, volume of distribution, and receptor sensitivity alter the pharmacokinetics and pharmacodynamics of virtually every antiparkinson agent, often in ways that increase both efficacy and toxicity at standard doses.
Levodopa pharmacokinetics are altered in older adults in several clinically relevant ways. Gastric emptying slows with age, producing more variable levodopa absorption and exaggerating peak-to-trough plasma fluctuations. Reduced renal clearance of carbidopa prolongs its plasma half-life; while this generally enhances peripheral AADC inhibition, it also increases the risk of drug accumulation at higher doses. Dietary protein intake, which competes with levodopa for transport across both the gut and the blood-brain barrier via the large neutral amino acid transporter, becomes proportionally more important as the motor therapeutic window narrows in advanced disease. Protein redistribution diets, in which protein is concentrated in the evening meal, are a practical strategy for patients experiencing meal-related wearing-off, but require careful nutritional counseling to avoid protein deficiency.3
Dopamine agonists are generally less well tolerated in older adults than in younger patients. The risks of orthostatic hypotension, hallucinations, and excessive daytime sleepiness are amplified by age-related changes in autonomic reflexes, cholinergic reserve, and sleep architecture. Impulse control disorders from dopamine agonists, while commonly discussed in younger patients, can also emerge in older adults and may be more difficult to detect when cognitive impairment already limits self-reporting. For these reasons, current guidelines generally recommend initiating antiparkinson therapy in patients over 70 with levodopa/carbidopa rather than with a dopamine agonist, and reserving agonists as adjuncts rather than first-line therapy in this age group. When dopamine agonists are used in older adults, pramipexole and ropinirole require renal dose adjustment; rotigotine transdermal may offer more stable plasma levels with fewer peak-effect adverse events.34
Falls are among the most consequential complications of PD in older adults, contributing to fractures, hospitalisation, loss of independence, and death. The pharmacological contributors to fall risk in PD are multiple and additive: orthostatic hypotension from levodopa and dopamine agonists, excessive daytime sleepiness from dopamine agonists, sedation from adjunct medications including benzodiazepines and quetiapine, anticholinergic burden from multiple medications, and the direct motor effects of fluctuating dopamine levels. A structured medication review specifically targeting fall risk should be performed at every clinic visit in older PD patients, with particular attention to the total anticholinergic burden, the presence of sedating agents, and the adequacy of orthostatic hypotension management. Reducing fall risk is frequently more urgent than optimizing motor function and should take priority when the two goals conflict.4
Prefer levodopa over dopamine agonists as initial therapy in patients over 70. Adjust renal dosing for pramipexole, ropinirole, and amantadine ER. Assess total anticholinergic burden at every visit. Orthostatic hypotension management takes precedence over motor optimization when fall risk is high. Avoid benzodiazepines and Z-drugs where possible; if sleep medication is needed, prefer melatonin or low-dose quetiapine.
A rare but clinically critical situation: managing Parkinson's disease pharmacotherapy during pregnancy and lactation, where the evidence base is limited to case series and preclinical data.
Parkinson's disease in women of childbearing age is uncommon but not rare, particularly in cases of young-onset PD. Pregnancy in a woman with established PD presents a pharmacological management challenge of considerable complexity: virtually all antiparkinson agents carry unknown or concerning fetal risk profiles, levodopa is the safest option but even its evidence base in human pregnancy is limited to case reports and small series, and untreated PD carries its own risks of falls, aspiration, and disability during pregnancy.
Levodopa is the antiparkinson agent with the longest human pregnancy experience. Although animal studies have shown skeletal malformations at high doses, human case series have not demonstrated a consistent teratogenic signal at therapeutic doses. The consensus among movement disorder specialists is that levodopa should be continued during pregnancy when motor symptoms are severe enough to impair safe functioning, at the lowest effective dose, in combination with carbidopa to minimise peripheral conversion. The timing of exposure matters: first-trimester organogenesis is the period of greatest theoretical concern. Decisions about continuing or adjusting levodopa therapy in pregnancy require individualized risk-benefit assessment and shared decision-making with the patient, preferably in consultation with maternal-fetal medicine.5
Dopamine agonists are generally considered riskier than levodopa during pregnancy and are typically discontinued or avoided when pregnancy is confirmed or planned, unless motor symptoms cannot be adequately controlled with levodopa alone. Bromocriptine, an ergot agonist, is the agent with the most pregnancy data because of its historic use in hyperprolactinemia; it is not clearly teratogenic but uterine contraction risk exists. Non-ergot agonists (pramipexole, ropinirole, rotigotine) have limited human pregnancy data and are classified on preclinical toxicology findings; they are generally avoided in the first trimester and used only if the clinical need outweighs the uncertainty. MAO-B inhibitors, COMT inhibitors, amantadine, and anticholinergics are all generally discontinued during pregnancy given the lack of safety data and the theoretical risks involved.5
Lactation presents a separate set of considerations. Levodopa is excreted in breast milk and may suppress prolactin, reducing milk production; its effects on the nursing infant are unknown. Dopamine agonists suppress lactation directly via D2 receptor-mediated prolactin inhibition, which may be relevant both therapeutically and as an adverse effect depending on the patient's breastfeeding intentions. The practical guidance in most cases is that breastfeeding while on antiparkinson medications should be discussed explicitly, and formula feeding may need to be recommended if medication continuation is necessary for maternal safety. Women with PD who are planning pregnancy or who become pregnant should be referred promptly to a movement disorder specialist experienced in this clinical scenario, as ad hoc decisions made without specialist input carry significant risk.5
Hormonal influences on PD have been investigated but remain poorly understood clinically. Estrogen has been shown to have dopaminotrophic effects in animal models, modulating dopamine synthesis, release, and receptor sensitivity. Epidemiological observations suggesting a lower PD incidence in women using post-menopausal hormone replacement therapy have not been confirmed in prospective randomised trials, and hormone replacement therapy is not currently recommended as a PD-modifying or neuroprotective intervention. The worsening of motor symptoms reported by some women during menstruation or at menopause may reflect changes in estrogen-mediated modulation of dopaminergic circuits, but no specific pharmacological intervention targeting this relationship is established.5
Continue levodopa/carbidopa if motor symptoms impair safe functioning, at lowest effective dose. Discontinue dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, and anticholinergics if possible. Refer to movement disorder specialist and maternal-fetal medicine jointly. Document shared decision-making explicitly. Review fall risk and aspiration risk at every antenatal visit. Advise that breastfeeding may need to be foregone if medication continuation is required.
The pharmacological risks of the surgical and procedural setting for the patient with Parkinson's disease, and how to protect against medication-related catastrophe during and after surgery.
Surgery and procedural sedation represent high-risk periods for patients with Parkinson's disease. The perioperative setting concentrates many of the most dangerous pharmacological hazards facing this patient population: dopaminergic medication interruption, exposure to dopamine-blocking antiemetics, aspiration from dysphagia, and interactions between antiparkinson drugs and anesthetic agents. Pre-operative planning and communication between the surgical team, anaesthesiologist, and movement disorder specialist are essential.
The most critical perioperative pharmacological principle is that levodopa must not be withheld for more than brief periods. Levodopa has a plasma half-life of approximately one hour, and the motor and non-motor consequences of levodopa withdrawal can manifest within hours. Prolonged nil-by-mouth periods before surgery must be managed with a plan for alternative levodopa delivery: rotigotine transdermal patches can be applied perioperatively and continued through the fasting period, maintaining basal dopaminergic tone without requiring oral intake. Where oral medications must be given on the day of surgery despite fasting, levodopa/carbidopa should be administered with a small sip of water as close to the procedure as anesthetic safety permits. Postoperatively, oral medications should be restarted at the earliest safe opportunity, and the surgical team must be explicitly informed that delays in restarting antiparkinson medications carry the risk of acute akinesia, aspiration pneumonia, and potentially life-threatening rigidity.6
Anesthetic agents interact with antiparkinson medications in several clinically relevant ways. Halothane is sensitized to catecholamine-induced arrhythmias when plasma levodopa concentrations are high; while halothane is now rarely used, the general principle of catecholamine sensitization is worth noting for other volatile agents at higher levodopa doses. Ketamine can cause sympathomimetic effects that are amplified in the dopaminergic state and should be used with caution. Propofol and isoflurane are generally considered acceptable for patients on antiparkinson therapy without specific contraindications. Regional anaesthesia is preferred over general anaesthesia when surgically feasible, as it avoids both the airway management challenges posed by dysarthria and dysphagia and the interaction landscape of inhaled agents. Neuromuscular blocking agents do not have specific PD-related concerns but the already-compromised respiratory function of many advanced PD patients demands careful dosing and monitoring of reversal.67
Postoperative delirium is common in PD patients following surgery and carries particular management challenges. The standard pharmacological approach to delirium management in general surgical populations, which frequently involves haloperidol, is contraindicated in PD due to severe motor worsening from D2 blockade. If pharmacological management of postoperative delirium is required in a PD patient, low-dose quetiapine 12.5–25 mg or pimavanserin are the safest options. Anticholinergics used for bronchospasm management (ipratropium, glycopyrrolate by the inhaled or parenteral route) and antiemetics (metoclopramide) are also contraindicated or require substitution with safer alternatives; ondansetron is the preferred antiemetic for intraoperative and postoperative nausea in PD patients because it has no dopamine receptor blocking activity.7
Never withhold levodopa for prolonged periods. Use rotigotine transdermal during nil-by-mouth periods. Give oral levodopa with the smallest safe sip of water as close to surgery as possible. Restart all antiparkinson medications at the earliest safe postoperative opportunity. Avoid metoclopramide; use ondansetron. Avoid haloperidol for delirium; use quetiapine 12.5–25 mg or pimavanserin. Communicate the complete antiparkinson regimen and its time-critical dosing to the entire perioperative team in writing.
Synthesising eight modules of antiparkinson pharmacology into a coherent, patient-centred, longitudinally sustainable treatment strategy.
The pharmacological management of Parkinson's disease is not a series of independent decisions made at isolated clinic visits. It is a longitudinal therapeutic relationship in which each addition, substitution, or withdrawal of a medication has consequences for the entire system. The clinician who manages PD over years must hold a dynamic model of the patient's full pharmacological burden, their current disease stage, their most pressing symptom priorities, and the risks they are most vulnerable to at any given time.
The architecture of a well-constructed antiparkinson regimen reflects disease stage. In early PD, the goal is symptom control with minimal adverse effects and maximum preserved quality of life; a single agent, typically levodopa/carbidopa in patients over 70 or a dopamine agonist in younger patients who prioritize delaying dyskinesia, is usually sufficient. As the disease advances over years, the wearing-off phenomenon develops and adjunct therapy becomes necessary; the sequence of COMT inhibitor or MAO-B inhibitor addition, individually or in combination, follows clinical need rather than a fixed protocol. In mid-to-late PD, when dyskinesia has emerged and non-motor symptoms have accumulated, the regimen expands to include amantadine ER for dyskinesia management, rivastigmine for dementia if present, pimavanserin for psychosis, and agents for autonomic and sleep disorders. Each addition must be justified, monitored, and periodically reassessed for continuing benefit versus accumulating adverse effect burden.8
Medication reconciliation is a continuous clinical duty in PD, not a one-time admission process. Patients with PD accumulate medications from multiple specialists and primary care providers, and the full pharmacological burden is frequently not visible to any single prescriber. Drugs added by cardiologists, urologists, psychiatrists, and general practitioners for comorbid conditions may carry significant antiparkinson interactions: calcium channel blockers can worsen parkinsonism, antidepressants interact with MAO-B inhibitors, bladder anticholinergics impair cognition, and proton pump inhibitors reduce levodopa absorption by raising gastric pH. A complete medication review including over-the-counter preparations, supplements, and herbal products should be performed at least annually and at any time of significant clinical change.9
Patient and caregiver education is an integral component of safe antiparkinson pharmacotherapy that is pharmacological in its implications even if it is not itself a drug intervention. Patients must understand the importance of consistent dosing timing, the risks of abrupt medication discontinuation, the significance of non-motor wearing-off as a signal to report rather than to self-treat, the foods and medications that interact with levodopa absorption, and the warning signs of impulse control disorders that require prompt reporting. Caregivers must understand the hospitalisation imperatives around antiparkinson medications and be equipped to advocate for their continuation in emergency and surgical settings. Written medication lists with dosing times should be carried by every patient with advanced PD and presented at every point of medical contact.9
The pharmacological management of PD is bounded at both ends by honest conversations about therapeutic goals. At the beginning of treatment, patients deserve an accurate picture of what medication can and cannot achieve: current therapy addresses symptoms without modifying the underlying neurodegenerative process, and the disease will continue to progress regardless of how well-optimized the regimen is. At the end of the treatment arc, as the disease reaches its advanced stages and the adverse effect burden of maximally complex regimens begins to exceed their benefit, palliative simplification of the antiparkinson regimen becomes appropriate. Reducing polypharmacy in advanced PD to focus on comfort, quality of daily life, and the prevention of medication-related harms is a legitimate and often underutilised clinical strategy that requires the same pharmacological expertise as the complex regimens it replaces.810
Early PD: monotherapy, minimal regimen, lifestyle counseling, fall prevention. Mid PD (wearing-off): add COMT or MAO-B inhibitor; assess for non-motor symptoms; begin cognitive monitoring. Advanced PD (dyskinesia, non-motor burden): amantadine ER if dyskinesia; treat psychosis, depression, OH, sleep; full medication reconciliation; fall assessment; caregiver education. Late PD: consider palliative simplification; prioritize comfort and quality of life over motor optimization.
1. Meperidine + any MAO-B inhibitor: fatal serotonin-like syndrome. 2. Metoclopramide in PD: severe motor worsening (D2 blocker). 3. Haloperidol/risperidone/olanzapine in PD: severe motor worsening. 4. Tramadol + MAO-B inhibitor: serotonin syndrome. 5. Ciprofloxacin + rasagiline: CYP1A2 inhibition raises rasagiline levels. 6. High-protein meals + levodopa: LNAA competition reduces brain uptake. 7. Tolcapone hepatotoxicity: mandatory LFT monitoring. 8. Anticholinergic burden in cognitively impaired PD: cognitive decline and delirium. 9. Dopamine agonist abrupt withdrawal: dopamine agonist withdrawal syndrome. 10. Levodopa withdrawal: acute akinesia and aspiration risk.